PCOS and Fertility: An Honest Guide for Indian Women Planning Pregnancy | ALIV

PCOS is the most common cause of anovulatory infertility in women globally — and in India, where PCOS prevalence is high, it represents a significant proportion of the couples presenting to fertility clinics every year. This clinical reality creates disproportionate fear when a PCOS diagnosis is first received, because the word "infertility" is associated with an impossibility of conceiving rather than what it actually means clinically: a reduction in the efficiency and regularity of the ovulation on which conception depends. The important clinical message — supported by very good evidence — is that the majority of women with PCOS who want to conceive do successfully conceive, most with relatively straightforward fertility support and many without any medical intervention at all.

Understanding Fertility in PCOS

The primary fertility challenge in PCOS is ovulatory dysfunction — irregular or absent ovulation means that the monthly window for conception is reduced or unpredictable. In women with completely regular ovulation, there is one opportunity per month for conception; in women with PCOS ovulating six to eight times per year, there are six to eight opportunities per year. This reduces the efficiency of natural conception significantly — but it does not eliminate it.

PCOS does not typically impair egg quality in younger women (under 35) to a clinically significant degree, and it does not impair implantation or the uterine environment once pregnancy is established. The challenge is predominantly the ovulation frequency and timing — which is addressable with relatively targeted interventions. Ovarian reserve in PCOS is typically high (elevated AMH) — paradoxically, PCOS patients often have excellent ovarian reserve in fertility terms, with many potential eggs available. The challenge is getting one of them to ovulate at the right time.

The Lifestyle Foundation Before Fertility Treatment

For overweight PCOS patients, weight loss of 5-10% of body weight is one of the most effective fertility interventions available — it improves insulin sensitivity, reduces androgen excess, and spontaneously restores ovulation in a significant proportion of patients. Studies show that spontaneous pregnancy rates after weight-related ovulation restoration in PCOS are comparable to rates after clomiphene induction in some populations. This is a meaningful clinical result, not a platitude, and it is worth prioritising before initiating pharmacological fertility interventions where appropriate.

Inositol supplementation — at the 2-4g per day dose with established evidence — improves oocyte quality, reduces androgen levels, and restores ovulation in a proportion of PCOS patients without pharmaceutical intervention. It is typically recommended for three to six months as a pre-conception optimisation measure before or alongside fertility treatment. See: evidence-based PCOS supplements.

Fertility Treatment Options in PCOS

Letrozole (aromatase inhibitor): Now the first-line ovulation induction agent for PCOS, supported by a landmark randomised controlled trial (NEJM 2014) showing superior live birth rates over clomiphene (the previous standard). Letrozole is a breast cancer medication used off-label for ovulation induction — the "off-label" status alarms some patients but the evidence quality for its use in PCOS is excellent and it is now the international standard recommendation.

Clomiphene citrate: Still widely used in India; effective in 60-80% of PCOS patients for ovulation induction. Less effective than letrozole for live birth rates in head-to-head comparison but remains a reasonable option where letrozole is unavailable or not tolerated.

Metformin combined with ovulation induction: Metformin as an adjunct to letrozole or clomiphene improves ovulation and pregnancy rates in insulin-resistant PCOS patients beyond either intervention alone.

IVF: Required for patients who do not respond to oral ovulation induction, or who have additional fertility factors (tubal disease, male factor) alongside PCOS. PCOS patients undergoing IVF have a risk of ovarian hyperstimulation syndrome (OHSS) — a serious potential complication of gonadotropin stimulation — that requires experienced clinical management to minimise. This is one of the most important PCOS-specific considerations in IVF management; discussing the OHSS risk management protocol with your fertility team before stimulation begins is an appropriate patient question.

How long should I try naturally before seeking fertility support?

Standard guidance: couples under 35 who have been trying for twelve months without conception should seek fertility evaluation. For women with known PCOS and irregular periods, this timeline is typically shortened — six months of trying with documented irregular cycles warrants investigation and ovulation induction consideration. For women over 35 with PCOS, six months is the standard benchmark before escalating to specialist evaluation. PCOS with anovulation does not improve without intervention — waiting the full twelve months while anovulatory is not clinically necessary.

Can ALIV support PCOS fertility planning?

ALIV's PCOS Balancer IV programme provides pre-conception optimisation support — improving the hormonal and metabolic environment before fertility treatment begins. The programme is most relevant in the three to six months before initiating pharmacological fertility treatment: improving insulin sensitivity, reducing androgen excess, addressing nutritional deficiencies (vitamin D, B12, ferritin, folate), and supporting antioxidant status for oocyte quality. ALIV complements gynaecological and fertility management — we work alongside your fertility specialist, not in place of them. See: the full PCOS support pillar.

Does PCOS increase the risk of pregnancy complications?

Yes — PCOS is associated with increased risk of gestational diabetes, pregnancy-induced hypertension, and pre-term birth. These risks are primarily mediated through the underlying insulin resistance and metabolic features of PCOS, and are lower in patients whose metabolic health was well-managed before conception. Antenatal monitoring appropriate for PCOS — including early gestational diabetes screening (earlier than the standard 24-28 week window) — should be discussed with the obstetric team from the first antenatal appointment.

Will PCOS affect me after I have finished having children?

PCOS does not resolve after childbearing — the metabolic risk factors (insulin resistance, dyslipidaemia, elevated cardiovascular risk) persist throughout the lifespan. Many women with PCOS find that their menstrual cycle becomes more regular in their late 30s and 40s as androgen levels naturally decline with age — but the metabolic substrate remains and can manifest as type 2 diabetes, cardiovascular disease, or metabolic syndrome in middle age if not managed. Post-childbearing PCOS care involves ongoing metabolic monitoring: regular fasting glucose and insulin, lipid panels, and blood pressure monitoring throughout the 40s and beyond.